Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Regarding the Gazette

Apologies, on re-reading your copy of my post I can see a possible conflct. Fortunately, any possible confusion was made moot by the concluding sentence:

.

Filing an Appeal, when none was apparently needed, by August 23, would also be a waste of resources and time of both the USPTO and Henneman

.

The salient point is not the extension nor Gazette confirmation but the fact of the NIRC. As stated, "all substantive issues have been resolved" which means that the patent will be revalidated to the satisfaction of both the examiner and Henneman

Then about 90 days later, provided there is no contesting of the amended patent as published in the NIRC

I would be most grateful if you would provide a link that shows how an ex parte NIRC may be contested.

.

.

Be well

Share
New Message
Please login to post a reply